We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
Merck (MRK - Free Report) ended the recent trading session at $99.75, demonstrating a -1.24% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.82%. On the other hand, the Dow registered a loss of 0.22%, and the technology-centric Nasdaq increased by 1.77%.
Heading into today, shares of the pharmaceutical company had gained 2.45% over the past month, outpacing the Medical sector's loss of 4.06% and the S&P 500's gain of 0.8% in that time.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on February 4, 2025. The company's upcoming EPS is projected at $1.80, signifying a 5900% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $15.52 billion, indicating a 6.06% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $7.72 per share and a revenue of $64.06 billion, signifying shifts of +411.26% and +6.56%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Merck. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.33% lower. At present, Merck boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Merck is at present trading with a Forward P/E ratio of 13.08. This indicates a discount in contrast to its industry's Forward P/E of 14.2.
It is also worth noting that MRK currently has a PEG ratio of 1.45. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.48 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 157, this industry ranks in the bottom 38% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Stock Sinks As Market Gains: Here's Why
Merck (MRK - Free Report) ended the recent trading session at $99.75, demonstrating a -1.24% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.82%. On the other hand, the Dow registered a loss of 0.22%, and the technology-centric Nasdaq increased by 1.77%.
Heading into today, shares of the pharmaceutical company had gained 2.45% over the past month, outpacing the Medical sector's loss of 4.06% and the S&P 500's gain of 0.8% in that time.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on February 4, 2025. The company's upcoming EPS is projected at $1.80, signifying a 5900% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $15.52 billion, indicating a 6.06% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $7.72 per share and a revenue of $64.06 billion, signifying shifts of +411.26% and +6.56%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Merck. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.33% lower. At present, Merck boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Merck is at present trading with a Forward P/E ratio of 13.08. This indicates a discount in contrast to its industry's Forward P/E of 14.2.
It is also worth noting that MRK currently has a PEG ratio of 1.45. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.48 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 157, this industry ranks in the bottom 38% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.